Skip to main content

Research Repository

Advanced Search

Outputs (3)

Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination (2021)
Journal Article
Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tanasescu, R., & Evans, J. R. (2021). Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Annals of Neurology, 90(2), 315-318. https://doi.org/10.1002/ana.26144

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS-CoV-2 vaccine. This rare neurol... Read More about Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.

Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells (2018)
Journal Article
Alkhattabi, N., Todd, I., Negm, O., Tighe, P. J., & Fairclough, L. C. (2018). Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells. Toxicology Letters, 299, 40-46. https://doi.org/10.1016/j.toxlet.2018.09.002

Cigarette smoke has significant toxic effects on the immune system, and increases the risk of developing autoimmune diseases; one immunosuppressive effect of cigarette smoke is that it inhibits the T cell-stimulating, immunogenic properties of myeloi... Read More about Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells.

Characterization of behavioral, signaling and cytokine alterations in a rat neurodevelopmental model for schizophrenia, and their reversal by the 5-HT6 receptor antagonist SB-399885 (2018)
Journal Article

Post-weaning social isolation of rats produces neuroanatomical, neurochemical and behavioral alterations resembling some core features of schizophrenia. This study examined the ability of the 5-HT? receptor antagonist SB-399885 to reverse isolation-i... Read More about Characterization of behavioral, signaling and cytokine alterations in a rat neurodevelopmental model for schizophrenia, and their reversal by the 5-HT6 receptor antagonist SB-399885.